Fund Details
OC
Overview
Investment portfolio
35rounds
| NAME | DATE | SIZE | |
|---|---|---|---|
Epicrispr | Aug 2026Led | $90 MSeries C | |
Bluejay Therapeutics | May 2024Participated | $182 MSeries C | |
Century Therapeutics | Apr 2024Led | $60 MOther Equity | |
ProfoundBio | Feb 2024Participated | $112 MSeries B | |
ArriVent Biopharma | Mar 2023Participated | $155 MSeries B | |
Allorion Therapeutics | Mar 2023Participated | $50 MSeries B | |
Aktis Oncology | Aug 2022Led | $84 MSeries A | |
Bluejay Therapeutics | Aug 2022Participated | $41 MSeries B | |
AnHeart Therapeutics | Dec 2021Led | $61 MSeries B | |
Allorion Therapeutics | Nov 2021Participated | $40 MSeries A | |
Sonoma BioTherapeutics | Aug 2021Participated | $265 MSeries B | |
Undercover Snacks | Jul 2021Led | $14 MOther Equity | |
Epicrispr | Aug 2026Led | $90 MSeries C | |
Bluejay Therapeutics | May 2024Participated | $182 MSeries C | |
Century Therapeutics | Apr 2024Led | $60 MOther Equity | |
ProfoundBio | Feb 2024Participated | $112 MSeries B | |
ArriVent Biopharma | Mar 2023Participated | $155 MSeries B | |
Allorion Therapeutics | Mar 2023Participated | $50 MSeries B | |
Aktis Oncology | Aug 2022Led | $84 MSeries A | |
Bluejay Therapeutics | Aug 2022Participated | $41 MSeries B | |
AnHeart Therapeutics | Dec 2021Led | $61 MSeries B | |
Allorion Therapeutics | Nov 2021Participated | $40 MSeries A | |
Sonoma BioTherapeutics | Aug 2021Participated | $265 MSeries B | |
Undercover Snacks | Jul 2021Led | $14 MOther Equity |
35 Items
35
Items
...
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Series A | 2 | 4 |
| Series B | 2 | 13 |
| Series C+ | 2 | 10 |
| Other Equity | 2 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Jun '20 | 2 |
| Jul '20 | 1 |
| Aug '20 | 1 |
| Sep '20 | 2 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 1 |
| Mar '21 | 7 |
| Apr '21 | 2 |
| May '21 | 5 |
| Jun '21 | 1 |
| Jul '21 | 1 |
| Aug '21 | 1 |
| Sep '21 | 0 |
| Oct '21 | 0 |
| Nov '21 | 1 |
| Dec '21 | 1 |
| Jan '22 | 0 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 2 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 2 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 1 |
| Mar '24 | 0 |
| Apr '24 | 1 |
| May '24 | 1 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 0 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 0 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 1 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 34 |
| Food & Agriculture | 1 |
| Professional Services | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 1 |
| $25M-$50M | 3 |
| $50M-$100M | 16 |
| $100M-$250M | 13 |
| $250M-$500M | 2 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 4 of 4 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 27 |
| China | 6 |
| Europe | 1 |
| Singapore | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Casdin Capital | 9 |
| Lilly Asia Ventures | 7 |
| RA Capital Management | 7 |
| Cormorant Asset Management | 5 |
| Fidelity Management & Research Company | 5 |
| HBM Healthcare Investments | 5 |
| Janus Henderson Investors | 5 |
| OrbiMed | 5 |
| Perceptive Advisors | 5 |
| Alexandria Venture Investments | 4 |
| Ally Bridge Group | 4 |
| ArrowMark Partners | 4 |
| EcoR1 Capital | 4 |
| Google Ventures | 4 |
| Mirae Asset | 4 |
| Novo Holdings | 4 |
| Surveyor Capital | 4 |
| Avidity Partners | 3 |
| BlackRock | 3 |
| Decheng Capital | 3 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 8 | 23% |
| Participating | 27 | 77% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 38% |
| Co-led | 5 | 63% |